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Seafood lipids encompass important healthy nutrients, such as n-3 polyunsaturated fatty acids (n-3 PUFAs), which
may have a significant effect on human cardiovascular health and needs to be supplied by the human diet. Particularly,
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the most abundant n-3 PUFA present in seafood and
have an impact on the cardiovascular health. DHA and EPA are deemed to display anti-inflammatory, cell membrane
modulation, and biophysical properties, thereby offsetting the pro-inflammatory effects of n-6 PUFA, and to reduce the
risk of cardiovascular disease. Consumption of large amounts of n-3 PUFA exerts a positive effect on a wide array of
cardiovascular health concerns ranging from hypertension and atherosclerosis to myocardial infarction and stroke. In
fact, animal studies indicate that n-3 PUFAs play a bioactive cardiovascular protective role. Therefore, it is recommended
up to two servings of fatty fish per week or up to 500 mg/day of EPA and DHA (World Health Organization).
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Seafood products are a rich source of lipids, including
some that are not found in other foods, such as n-3
polyunsaturated fatty acids (n-3 PUFAs), particularly, the
very important n-3 PUFA, eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids [1, 2]. The abundance of
the fatty acids (FAs) in seafood products (fish, crusta-
ceans, cephalopods, bivalves, etc.) varies widely. It is well
known that seafood composition depends on many fac-
tors, such as species, sex, sexual maturity degree, size,
location, water temperature, type of feeding, and season
[3]. The variation in the FA composition is explained by
fluctuations in the quality and amount of available food,
especially phytoplankton [4]. Seafood FAs are typically
part of larger molecules, such as triacylglycerols (TAGs).
However, these molecules have to be hydrolysed into
FAs in the human gut in order to be absorbed. The effi-
ciency of this hydrolysis as well as other factors (chem-
ical affinity, protein-lipid interactions) is crucial for the
level of FA bioaccessibility and bioavailability, which is
important for a proper evaluation of the effects of sea-
food lipids on health.
On the other hand, evidence has been accumulating of
the importance of n-3 PUFA in the prevention and* Correspondence: carlos.cardoso@ipma.pt
1Division of Aquaculture and Upgrading, Portuguese Institute for the Sea
and Atmosphere (IPMA, IP), Av. Brasília, 1449-006 Lisbon, Portugal
2CIIMAR, Interdisciplinary Centre of Marine and Environmental Research,
University of Porto, Rua dos Bragas 289, 4050-123 Porto, Portugal
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zetreatment of cardiovascular disease (CVD), since the first
cross-cultural epidemiologic studies conducted in the
1970s [5]. Evidence from observational studies, random-
ized controlled trials (RCTs), and clinical, animal, and
in vitro studies suggests that higher intake of very long-
chain n-3 PUFA found in fatty fish or fish oil supple-
ments, namely, EPA and DHA, may reduce CVD risk
[2]. EPA and DHA can be synthesized from α-linolenic
acid (ALA) in humans, but most studies suggest that
humans only convert <5 % of ALA to EPA [6] and
<0.05 % of ALA to DHA [7]. This is related to the over-
all low activity of enzymes essential for this conversion
in mammals, namely, elongase, desaturase, and peroxi-
somal β-oxidation enzymes [8]. It is assumed that through
elongation and desaturation, ALA is converted to EPA
and 22:5 n-3. Afterwards, this FA is elongated to 24:5 n-3,
which is desaturated to 24:6 n-3, and, finally, is metabo-
lized via β-oxidation to DHA. This is a relatively demand-
ing metabolic route that makes a high synthesis of EPA
and especially DHA from ALA difficult.
This review will be focused on the effects of seafood
lipids on the cardiovascular system and main-related
health problems and outcomes.Main seafood lipids and their contents
Seafood products contain a wide variety of lipid classes,
ranging from TAG, free fatty acids (FFAs), and sterols
(cholesterol) to phospholipids (PL). These lipids arele is distributed under the terms of the Creative Commons Attribution 4.0
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acid (FA) moiety. Among these FAs, n-3 PUFAs repre-
sent a large share [9]. Particularly, marine fish and shell-
fish are rich sources of EPA (20:5 n-3) and DHA (22:6
n-3) [10]. In wild fish, EPA and DHA may represent as
much as 90 % of the total PUFA [11]. EPA and DHA are
considered to be essential FAs in that they cannot be
biosynthesized with a level of efficiency sufficient to
meet human needs [12]. In fact, there have been several
studies pointing to a very limited extent of α-linolenic
(ALA, 18:3 n-3) conversion to EPA and DHA [13, 14].
However, farmed fish have a different FA profile due to
the incorporation of vegetable oils and other vegetable
materials containing fat in their diets. Indeed, their FA
profile shows high levels of oleic acid as well as n-6
PUFA and is less rich in EPA and DHA [15].
Regarding saturated fatty acids (SFAs), palmitic acid
(16:0) is the main SFA in fish, being found in all lipid
classes (TAG, PL, others). Indeed, according to results
attained in herring [16, 17], 16:0 is a key metabolite and
its content is not significantly affected by fish feeding.
Myristic acid (14:0) and stearic acid (18:0) have lower
percentages, and the first of these is preferably in TAGs.
The SFAs with longer chain such as 20:0, 22:0, and 24:0
are typically found at levels below 1 % [18]. FAs with an
odd number of carbon atoms have also been detected
and are probably derived by oxidation of the alcohol
present in copepods or microorganisms. [19] Indeed, it
has been claimed that these organisms biosynthesize FAs
via propionyl-coenzyme A leading to less usual FAs [20].
The most abundant monounsaturated fatty acid (MUFA)
in seafood lipids are usually palmitoleic acid (16:1 n-7)
and oleic acid (18:1 n-9). It has been shown that, for a
given species, the sum of the 16:1 and 18:1 contents was
almost constant and this has been justified with the obser-
vation that the level of these FAs is controlled by the or-
ganism metabolism [21]. With regard to MUFAs with aTable 1 Lipid, total PUFA, EPA, and DHA contents of several bivalve
Fish species Lipid content
(g/100 g wet weight)
Common cockle (Cerastoderma edule) 3.3
Grooved carpet shell (Ruditapes decussates) 0.9
European squid (Loligo vulgaris) 0.9
Common octopus (Octopus vulgaris) 1.2
Norway lobster (Nephropus norvegicus) 0.5
Atlantic salmon (Salmo salar) 21.9
Black scabbardfish (Aphanopus carbo) 2.8
European hake (Merluccius merluccius) 0.7
Horse mackerel (Trachurus trachurus) 2.2
Monkfish (Lophius piscatorius) 0.2
Sardine (Sardina pilchardus) 10.9long chain, such as 20:1 and 22:1, they appear to have an
exogenous origin, possibly from copepods [22]. These FAs
are not involved in the structure of membranes. There is
also a MUFA with 24 carbon atoms whose content does
not exceed 1 % [23].
The lipid content and total PUFA, EPA, and DHA con-
tents of representative seafood are presented in Table 1.
The FA profiles of seafood are quite well studied, be-
ing available huge masses of FA data in national food
composition tables in the internet [24] and in books
[25]. Some systematic studies on the FA profile in sea-
food have been done in Europe [26, 27]. This profile var-
ies considerably with temperature, salinity, and the type
and availability of food, factors which, in turn, are af-
fected by geographical area and by season [28]. Studies
have shown that the water temperature has an effect on
the FA composition of carp [29]. It was reported that a
decrease in temperature leads to a higher PUFA content
due to an enhanced activity of desaturases, which con-
tribute to the biosynthesis of more unsaturated FAs
(with lower melting point) in order to keep their physio-
logical role. Nonetheless, it must be stressed that FA
profile in seafood results from a balance between FAs
from diet and those formed by biosynthesis [30]. But,
whenever food is rich enough in the necessary FAs, fish
and other aquatic organisms do not spend energy in FA
biosynthesis [31].
The lipid bioaccessibility and bioavailability
Seafood lipids have an important role in human nutri-
tion. However, for an appropriate assessment of their
importance and role in health, it is fundamental that in-
stead of dealing with the total contents of seafood lipids,
the contents of the FAs and other lipid components that
are available to intestinal absorption after digestion of
cooked seafood in a typical meal be accounted for using
appropriate methodologies. Indeed, the level of lipids inmollusks, cephalopods, crustaceans, and fish [26]
Total PUFA n-3 PUFA (mg/100 g wet weight)
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from the bioaccessible level, that is, the lipid concentra-
tion that is released from the seafood matrix into the
intestinal lumen after digestion and is available for ab-
sorption [32, 33]. On the other hand, bioavailability is
usually defined as the fraction of an oral dose of a sub-
stance that reaches the systemic circulation [34]. The
bioaccessible content is always equal or higher than the
bioavailable content [32]. Bioaccessibility is determined
by in vitro simulations of human digestion [32, 35]. For
bioavailability, according to the definition given above,
cell lines and transwell assays are used for the simula-
tion of the intestinal lining barrier [36] and cell cul-
tures mimicking the relevant liver tissues may also be
used [37].
For better grasping the concepts, lipid digestion has to
be duly understood. Indeed, the digestion of the seafood
lipids is composed of three distinct phases. Firstly, lipids
are physically and chemically modified resulting in sim-
pler molecules, for instance, TAGs generate FAs and gly-
cerol [38, 39]. The gastric and pancreatic lipases catalyze
the hydrolysis of FAs, leading to monoacylglycerols
(MAGs) type sn-2 and free fatty acids (FFAs). Secondly,
digested material is transported into the intestinal mu-
cosa. Finally, the digested molecules are reconstituted.
This reconstitution is related to transport of FAs (as FFA
or MAG) to the lymph and the blood. For this transport
to occur, FAs are re-esterified to TAG (rTAG) in the
endoplasmic reticulum of enterocytes [40]. All the afore-
mentioned processes may affect lipid bioavailability.
Bioaccessibility should be studied under realistic con-
ditions, which entails taking into account the effect of
culinary treatments upon seafood lipids. Hence, a first
step towards a more accurate determination of the lipids
effectively provided by any given diet containing seafood
entails cooking foods according to the typical culinary
methods [41, 42]. Boiling, grilling, roasting, frying, and
other culinary treatments can alter lipid content either
by leaching it out or decomposing it or concentrating it
due to water loss. Moreover, cooking generates several
biochemical and physical transformations that bring
about relevant matrix changes, which, in turn, affect sea-
food lipid bioaccessibility [41, 42]. Indeed, it was observed
that grilled fish displayed lower FA bioaccessibility than
raw fish. For instance, the lipid bioaccessibility in meagre
(Argyrosomus regius) was reduced from 89 % in the raw
fish to 68 % in the grilled fish [41]. This was probably due
to the very harsh thermal treatment (180 °C and direct
conductive heat) associated to grilling. Under these ex-
treme heating conditions, protein denaturation is en-
hanced and digestibility is reduced because covalent
bonds between polypeptide chains are established [43]. In
fact, there was also a reduction of protein digestibility with
grilling. It thence appears that protein aggregates formedduring grilling trap a significant portion of the lipids,
thereby reducing lipid bioaccessibility [41].
Besides cooking-related changes, other factors affect
seafood lipid bioaccessibility deviating it from the ideal
100 %. It is important to stress that the different physical
and chemical properties of each lipid compound, such as
each FA, influence processes such as digestion, absorp-
tion, and transport in blood [44]. Indeed, it has been
shown that FA bioaccessibility in salmon (Salmo salar)
is reduced as the number of double bonds increases
[42]. Hence, n-3 PUFAs with three or more double
bonds (a very high level of unsaturation) present low FA
bioaccessibility. For instance, while erucic acid (22 car-
bons and one double bond) exhibited a bioaccessibility
of 93.9 % in raw fish, the bioaccessibility of DHA (22
carbons and six double bonds) was only 73.5 % in the
same raw fish [42]. This phenomenon may be explained
by three main causes: chemical affinity of each FA, di-
gestive lipases favoring the hydrolysis of less unsaturated
FAs, [45] and location of n-3 PUFA (namely, EPA and
DHA) in the sn-2 position of TAGs, which is less access-
ible to lipases, particularly the important pancreatic lip-
ase [40].
Bioaccessibility and, as a consequence, bioavailability
of FAs may also depend on the chemical binding form
(FA bound in ethyl esters, EE, TAG, or PL) [40]. It has
been observed in in vivo studies with humans that FAs
bound in TAG are more bioavailable than FAs bound in
EE form [46, 47]. The latter form is found sometimes in
n-3 PUFA supplements. A first explanation for this dif-
ference may be found in in vitro studies showing that
pancreatic lipases hydrolyze EEs 10 to 50 times less effi-
ciently than glycerol esters in TAGs [48]. Another rea-
son may be differences in the re-esterification of FAs to
TAG after absorption. This process requires glycerol and
2-MAG, which are readily available when FAs are bound
in TAG, but absent when FAs are bound in the EE
form, since there is no release of glycerol during di-
gestion in this case. Accordingly, re-esterification may
be delayed due to difficulties in providing the missing
glycerol [49].
In krill oil, which is rich in PLs, it has been claimed
that its FA bioavailability is higher on the basis of in vivo
studies [50–52]. This higher bioavailability may be re-
lated to the high share of PLs. Taking into account that
FFAs also exhibit a high bioavailability [46, 53] because
no chemical bond needs to be broken and that rTAG
seem to have a bioavailability higher than natural fish oil
(TAGs) and FFAs [46], it can be put forward a possible
FA bioavailability order: rTAG>TAG~FFA>EE, with the
position of PL above that of TAG. Nonetheless, more
scientific research is necessary for proving this order, es-
pecially concerning a supposed higher bioavailability of
PLs with respect to TAGs and even rTAGs.
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and other health effects
Studies’ results in the recent decades show that morbid-
ity and mortality related to chronic diseases in the gen-
eral population have a multifactorial origin, resulting
mostly from the interaction between genetic and dietary
factors. The results from current epidemiological, clin-
ical, and experimental studies allow concluding that
dietary patterns have a profound influence on health
outcomes and well-being of populations. Many studies
also indicate that the major groups of FAs are associated
with different health effects and confirm that modula-
tion of dietary lipid composition affects lipid concentra-
tions and composition in the blood. Thence, Public
Health Institutes and Health Associations as well as
many western country authorities have advised inde-
pendently daily amounts for each group of SFA, PUFA,
and long-chain PUFA (LC-PUFA) [54–56].
SFAs have been cited as responsible for a minor in-
crease of HDL-cholesterol; however, such positive effect
does not avoid the harmful increase of low-density lipo-
protein (LDL) cholesterol and plasma TAG [57]. For the
other lipid groups, there is a large body of epidemio-
logical evidence about the different health aspects.
Although the available information about the health
benefits of MUFA is not as broad and convincing as for
PUFA, there is a considerable level and strength of evi-
dence. MUFAs are considered more stable than PUFA
and more resistant to oxidation [58]. Namely, oleic acid
may prevent the development of atheromas and subse-
quent thrombi due to its impact on MUFA/SFA ratios,
oxidation resistance, and induction of large hydrolysable
chylomicrons (CM). Oleic acid and MUFA consumption
decreases platelet sensitivity and aggregation and in-
creases fibrinolysis. However, a full mechanistic explan-
ation of the ability of dietary MUFA to decrease platelet
aggregation has yet to be determined [59]. Most notice-
able effects of MUFA come from studies where the sub-
stitution of SFA by oleic acid has been tested. The
consumption of MUFA, especially oleic acid, has been
shown to decrease plasma TAG and cholesterol concen-
trations, without affecting plasma high-density lipopro-
teins (HDL) levels in healthy subjects [60]. Based on the
data of nine intervention studies on the cardiovascular
(CV) effects of milks containing EPA and DHA and/or
oleic acid, it was concluded that these types of enriched
milks in the context of a balanced diet and healthy life-
style lead to desirable CV effects. Regarding the relation-
ship between oleic acid intake and cancer risk, this
MUFA may have a potential role in lowering the risk of
breast and stomach cancer, as well as in ovary, colon,
and endometrium cancer [61, 62]. It has been hypothe-
sized that the anticancer effect may relate mainly to the
ability of oleic acid to regulate oncogenes [63]. However,both SFA and MUFA are FA classes that may be attained
from many different food sources and not specific to
seafood.
The benefits from the ingestion of n-3 PUFA were
demonstrated some years ago with studies in Inuit popu-
lations of Greenland Eskimos of Alaska fishermen and
coastal areas of Japan. Studies revealed that the risk of
CVD was higher in Caucasian populations, compared
with the Inuit populations studied. These same studies
showed that the Eskimos had a lower level of plasma
cholesterol, TAG and very low-density lipoprotein (VLDL)
and a higher level of HDL, despite a higher fat intake from
mammals and fish. The major cause was ascribed to the
high n-3 PUFA intake in the traditional Inuit diet com-
pared with the typical Caucasian population diet [64, 65].
In addition, the two most important n-3 PUFAs, DHA
and EPA, are deemed to display some anti-inflammatory
properties, thereby offsetting the pro-inflammatory effects
of n-6 PUFA [66].
Moreover, studies on humans and experimental animal
studies indicate that consumption of LC-PUFA fosters
calcium absorption, increasing bone density [67]. A
strong correlation between dietary intake of DHA and
EPA and the consequent increase in bone calcium and
reduced urinary deoxypyridinoline [67] was also ob-
served. Possible mechanisms underlying these effects
have been related with the renal calcium metabolism,
the inhibition of the production of inflammatory cyto-
kines that act as stimulants of osteoclastic bone resorp-
tion, and the regulation of the normal balance between
bone and ectopic calcification.
Several epidemiological studies also pointed out a
beneficial effect of ingesting daily doses of EPA/DHA on
the risk of certain cancers such as breast cancer, prostate
cancer, and colon cancer [68]. DHA is selectively con-
centrated in the synaptic and retinal membranes, and it
is thought to be related to visual function, brain develop-
ment, behavior, and learning. Indeed, some studies have
shown that DHA concentration in blood plasma in preg-
nant women is related with properties in visual and
cognitive development of children [69]. Other studies in-
dicate the beneficial effect of n-3 PUFA at the neuro-
logical level as well as regarding antidepressive and
mental health [69, 70]. Indirectly, the intake of EPA/
DHA can be linked to the prevention of the develop-
ment of type 2 diabetes due to decreased activation of
transcription factor NF-kB (nuclear factor kappa-light-
chain-enhancer of activated B cells) associated with
increases in the activity of PPAR (peroxisome proliferator-
activated receptors) from peroxisome (Fig. 1). Specifically,
EPA/DHA either directly or through their prostaglandin
and leukotriene derivatives activate PPARs, which hetero-
dimerize with the retinoid X receptor (RXR) and operate
together with coactivators (Coact), and these sets PPAR-
Fig. 1 Scheme highlighting the connection between EPA and DHA in diet and alterations in gene transcription leading to less FA in circulation
and less insulin resistance
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their transcription and leading to an increase of FA stor-
age in adipocytes, thereby reducing the FAs in circulation.
This, in turn, fosters carbohydrate oxidation as an energy
source for cell metabolism. On the other hand, the bind-
ing of PPAR to Coacts seems to reduce the levels of Co-
acts available for binding to NF-kB. As a result, there is a
reduction of NF-kB activation that may decrease the ex-
pression of the transmembrane receptor for advanced
glycosylation end products, which is associated to athero-
sclerosis and diabetes [71]. It seems that n-3 PUFA intakehas a therapeutic effect in lowering levels of total TAG
and preventing type 2 diabetes, playing a protective role
against lipid peroxidation [72]. Thus, the importance of
seafood EPA and DHA to health is quite evident.
n-3 PUFA and the cardiovascular system: evidence
Among seafood lipids, the n-3 PUFAs are the most rele-
vant concerning cardiovascular health. Indeed, the n-3
PUFAs have been linked to benefits for the cardiovascu-
lar system [64, 65]. Epidemiological studies have con-
firmed that the fat consumed by the Inuit population
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was correlated with a cardioprotective effect on the
CVD risk [64, 73]. Further studies in this area have
been published. Namely, two important intervention
studies have found a cardioprotective effect of EPA
and DHA consumption:
(1)The DART—Diet and reinfarction trial—was a study
of secondary prevention, in which male individuals,
who had previously suffered a myocardial infarction
(MI), ingested over 2-year oil capsules with 900 mg/
day of EPA and DHA or 200–400 g/week of fatty
fish containing 500–800 mg/day of n-3 PUFA. The
study showed a 29 % reduction in overall mortality
as a result of fatty fish intake [74].
(2)The GISSI, “Gruppo Italiano per Studio della
Sopravvivenza nell miocardio Infarction,” a
secondary prevention study with 11,324 patients
surviving a myocardial infarction, which for
42 months received capsules with 850 mg/day of
EPA + DHA with or without vitamin E. In both
cases, there was a 15 % reduction in deaths due to
heart attack or stroke. The overall mortality
decreased by 21 % and sudden death caused by
heart disease fell by 45 % [75].
On the other hand, there have also been meta-analysis
studies that draw on intervention and/or epidemiological
studies and try to assess the level of evidence. Namely, a
comprehensive analysis of 11 studies, comprising 222,364
people and an average follow-up of 11.8 years, showed that
the relative risk of cardiovascular disease was 0.85 for eating
fish once a week, 0.77 for two to four times per week and
0.62 for ≥5 times per week compared to people with an in-
take of less than a monthly portion of fish. Furthermore,
for each increase in fish consumption of 20 g/day, a de-
crease of 7 % in mortality from CVD was determined [76].
In most studies, risk reduction has been observed
for fatal coronary heart disease (CHD) [76] and less
consistently for non-fatal coronary events [77]. In
addition to benefit from moderate fish intake, it was
found in a Japanese cohort that the risk of CHD
events has been lower in individuals consuming fish,
at least, eight times per week than in those consum-
ing only once a week [77]. However, this was not ob-
served in another Japanese cohort study [78]. In
general, studies provide evidence for beneficial effects
on the risk of fatal CHD events in individuals con-
suming fish in moderate amounts, but the extra
health benefit from higher consumption is still dis-
puted. Moreover, there are specific groups deserving
special attention. Namely, in diabetic patients with a
high risk of CHD, beneficial associations between fish
intake and CHD risk have been reported [79].The omega-3 index (the sum of the content of EPA
and DHA in erythrocyte membrane) was proposed as a
new risk factor for CHD evaluation [80]. From the ana-
lysis of the relationship between omega-3 index and risk
of death from CHD, these authors concluded that this
risk decreased by 90 % when the omega-3 index in-
creased 4 % to greater than 8 %. These authors also de-
fined a scale for assessing risk of death from CHD using
this index of omega-3: 0–4 % area of highest risk; 4–8 %
zone of intermediate risk; and more than 8 %, low risk
area [80].
All the aforementioned studies show that there is a
significant amount of evidence associating cardiovascu-
lar health benefits and fatty fish consumption with par-
ticular importance of EPA and DHA contents. It should
also be noted that the fat level of fish and its culinary
preparation methods are possible confounders in study-
ing the relationship between fish intake and CHD risk.
Therefore, further study is still required for consolidat-
ing evidence, ascertaining the most adequate levels of
EPA and DHA intake and the special needs of particular
population groups.
n-3 PUFA and the cardiovascular system:
mechanisms and particular effects
The relationship between n-3 PUFA, namely, EPA and
DHA, and the cardiovascular system has elicited many
studies concerning the mechanisms underlying this con-
nection. Such studies may shed light into the subject
and provide help in modulating fish consumption and
EPA +DHA intake for a maximal cardiovascular health
benefit.
Originally, the benefits associated to the consumption
of n-3 PUFA were ascribed to antithrombotic effects.
However, more recent studies point to the predomin-
ance of the antiarrhythmic benefits of n-3 PUFA intake.
It was found that supplementation of n-3 PUFA in pa-
tients who suffered myocardial infarction was correlated
with decreased risk of mortality associated with cardiac
arrhythmia [2]. Permeability modulation of the plasma
membrane in the stabilization of the ion channels sug-
gests that EPA/DHA may have protective properties in
the cells of the heart muscle tissue. This effect is
achieved through the enrichment of cardiac membranes
in EPA and DHA [2, 81].
Another route for the cardiovascular benefits of n-3
PUFA may be the lowering of blood pressure. Indeed,
consumption of oily fish high in DHA such as anchovy,
herring, mackerel, and salmon has been suggested to de-
crease blood pressure in some individuals [82, 83]. DHA
appears to have a more important role than EPA in lower-
ing blood pressure. This decrease could be related to in-
hibition of the renin-angiotensin system (RAS), including
angiotensin converting enzyme (ACE), thereby inhibiting
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sible for the increase in blood pressure [84, 85]. More re-
cently, it has been argued that n-3 PUFA lower blood
pressure by directly activating large-conductance Ca2+-
dependent K+ channels [86].
Intake of daily doses of n-3 PUFA is also associated
with improvements in the reduction of atherosclerotic
platelet aggregation as well as decreased production of
clotting factors and fibrinolytic factors [80, 87]. For ath-
erosclerosis, a study [88] has indicated that the dietary
intake of long-chain n-3 PUFAs or non-fried fish can be
brought together with a lower prevalence of subclinical
atherosclerosis classified by common carotid intima-
media thickness (cCIMT), although significant changes
in internal CIMT (iCIMT), coronary artery calcium
(CAC) score, and ankle-brachial index (ABI) were not
observed. These findings also suggested that the associ-
ation of fish and atherosclerosis may vary depending on
the type of fish meal consumed and the ways used to
measure atherosclerosis. Regarding the precise under-
lying mechanisms for the n-3 PUFA effects on athero-
sclerosis, different hypotheses have been put forward
over the years. Namely, platelet-derived growth factor
(PDGF) has been proposed to play a key role in the
development of advanced atherosclerotic lesions by
stimulating the migration and proliferation of vascular
smooth muscle cells [89], and n-3 PUFA has been re-
ported to significantly inhibit PDGF-induced migration
[90]. It has also been shown that atherosclerotic plaques
readily incorporate EPA and a higher EPA plaque con-
tent is associated with a reduced number of foam cells
and T cells, less inflammation, and increased plaque sta-
bility [91]. Hence, an alternative n-3 PUFA protective
mechanism of action could be the stabilization of ath-
erosclerotic plaques through the anti-inflammatory ac-
tions of some particular n-3 PUFA.
Among the possible mechanisms for the intake of n-3
PUFA to reduce CVD and platelet stability, the effect on
decreasing the total lipids in plasma, TAG (approxi-
mately 25–30 %), and VLDL production [64, 92] is de-
scribed. Studies also indicate that consumption of n-3
PUFA is related to the biophysical properties of cell
membranes (namely, membrane fluidity enhancement
due to the highly unsaturated degree of DHA) as well as
to the relaxation of the endothelium, the path involving
vasodilatation, enhanced by increased production of NO
(nitric oxide), and/or by suppression of the influx of Ca2+
through the channel activated by transmembrane poten-
tial differences in smooth muscle cells and endothelium.
Inhibition of these channels also contributes to the reduc-
tion of the large and rapid fluctuations in the concentra-
tion of free Ca2+, which, in turn, favors the reduction of
ventricular arrhythmias—seen with supplementation with
fish oil capsules [44, 93].This last aspect is very important, since both fatal cor-
onary heart disease (CHD) and sudden cardiac death
(SCD) most often share fatal ventricular arrhythmia as a
final common pathway [94]. Observational studies, ran-
domized clinical trials, and experimental studies provide
concordant evidence that not very high consumption of
fish or fish oil (about 250 mg of EPA + DHA/day) de-
creases the risk of CHD death and SCD. The magnitude
of the effect is also important, with pooled analysis indi-
cating 36 % lower risk of CHD death with modest con-
sumption compared with no consumption [94].
A beneficial effect of n-3 PUFA on the prevention of
stroke [95] through the reduction of blood cholesterol
[96] and blood pressure [86] has also been reported. Fur-
thermore, in an experimental study with mice, it has
been claimed that n-3 PUFA supplementation is a poten-
tial angiogenic treatment capable of augmenting brain re-
pair and improving long-term functional recovery after
ischemic stroke [97]. Mechanistically, n-3 PUFAs were
able to induce upregulation of angiopoietin 2 (Ang 2) in
astrocytes after transient focal cerebral ischemia and stim-
ulated extracellular Ang 2 release from cultured astrocytes
after oxygen and glucose deprivation. Ang 2 facilitated
endothelial proliferation and barrier formation in vitro by
potentiating the effects of vascular endothelial growth fac-
tor, for instance, on phospholipase Cγ1 [97].
Therefore, CVD—an entity that includes arterioscler-
osis, atherosclerosis, thrombosis, myocardial infarction,
and stroke, provided that the occurrence of stroke is re-
lated to the physiological condition of a blood vessel [98]
and that has high blood pressure, hyperlipidemia, and
hyperglycemia as risk factors—may be prevented and miti-
gated by n-3 PUFA intake through reduction of, at least,
two major factors: hypertension and hyperlipidemia.
Seafood lipids and cardiovascular health: dietary
recommendations
In general, dietary advices acknowledge the importance
of seafood lipids, thereby prescribing a weekly consump-
tion of one to two portions of fatty fish [99]. Particularly,
there are currently numerous recommendations for the
intake of n-3 PUFA for the prevention of deficiency in
essential FAs and to decrease the risk of developing car-
diovascular disease. The World Health Organization
(WHO) recommends for the prevention of CVD and is-
chemic stroke, the intake of n-3 PUFA in the diet should
represent 6 to 10 % of total energy intake (5–8 % n-6
PUFA and 1–2 % n-3 PUFA), and a regular intake of one
to two servings of fatty fish per week, equivalent to 200
to 500 mg/day of EPA and DHA [56]. Moreover, the
EPA +DHA recommendation daily intake (RDI) by the
European Food Safety Authority (EFSA) based on car-
diovascular risk considerations for European adults is
between 250 and 500 mg/day1, and the American Heart
Cardoso et al. Nutrire  (2016) 41:7 Page 8 of 10Association (AHA) recommends a daily intake of 400–
500 mg of EPA +DHA [100].
Conclusions
Seafood lipids are a quite vast set of molecules compris-
ing TAG, FFA, PL, sterols, and others. The molecules
mainly yield FA molecules after digestion in the human
gut. The bioaccessibility and bioavailability of these FAs
depend on diverse factors, namely, degree of saturation
and chemical binding form. The bioavailable FAs are the
fraction of the seafood lipids that has the largest effect
on human health. Different classes of FAs (SFA, MUFA,
n-3 PUFA) exert an influence upon health outcomes.
Among these, cardiovascular health is much improved
by the n-3 PUFA and, particularly, by EPA and DHA. It
has been found that n-3 PUFA has antiarrhythmic bene-
fits, reduces atherosclerotic platelet aggregation, dimin-
ishes the prevalence of subclinical atherosclerosis, and
lowers blood pressure. Nevertheless, the underlying mech-
anisms are not completely understood and require further
experimental studies for a deeper knowledge. The men-
tioned beneficial effects help to explain the positive impact
of n-3 PUFA on CHD and SCD as well as in other CVDs,
such as stroke. Accordingly, it is recommended up to two
servings of fatty fish per week or up to 1000 mg/day of
EPA and DHA.
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